Anders Gustavsson is co-author of a recently published Alzheimer study presenting a cross-walk between the generic health utility measure EQ5D and the disease specific health-related quality of life measure QoL-AD.
A free full text version is available here.
Anders Gustavsson, Partner at Quantify, is a panelist at a HTAi symposium on the value of delaying progression in early Alzheimer’s disease on October 13, sponsored by Biogen.
See full program on https://htai.eventsair.com/htaibeijing2020/#program.
[…]
Coordinated by EMA, the European Network of Centers for Pharmacoepidemiology & Pharmacovigilance (ENCePP) is an initiative that brings together expertise and resources in pharmacoepidemiology and pharmacovigilance across Europe with the aim to facilitate the conduct of high quality, multi-center, independent […]
Do you have experience in market access, RWE, and project leading? Do you want to work in an exciting international environment at a growing HEOR consultancy? Are you a team player with an analytical mindset and a proven track record? […]
The paper “Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study” by Quantify’s Kirk Geale and coauthors has been published in JAMA Dermatology. […]
The abstract “Persistence of biologic treatment in psoriatic arthritis: A population-based study in Sweden”, co-authored by Quantify’s Kirk Geale, Ingrid Lindberg and Emma Paulsson, has been accepted for oral presentation at EULAR 2020 E-Congress on June 3rd at 16:30-16:35, Session […]
The paper “Statin Dose Titration Patterns and Subsequent Major Cardiovascular Events in very High-Risk Patients – Estimates from Swedish Population-based Registry Data”, co-authored by Quantify’s Jonas Banefelt and Maria Lindh has been published in European Heart Journal – Quality of […]
The paper ‘Fragility fractures in Europe: burden, management and opportunities’, co-authored by Quantify’s Fredrik Borgström, Linda Karlsson, Gustaf Ortsäter and Nicholas Norton, has been published in Archives of Osteoporosis.
Quantify is pleased to announce the appointment of Kirk Geale as the new CEO of Quantify Research, replacing Åsa By after 7 highly successful years. Quantify is grateful to Åsa for the visionary leadership and energy she brought to the […]
The paper ‘Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden’, co-authored by Quantify, has been published in PharmacoEconomics. Read the full article here.
